🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

An interesting paper in PNAS discussing the development of a nanobody treatment against obligatory intracellular bacterium Ehrlichia chaffeensis. One of the coauthors, Prof. Dehua Pei, is an invited speaker at our annual conference on Oct. 15th and 16th pnas.org/content/118/18…

Prof. Jinbo Xu and colleagues present their deep ResNet on protein structure prediction with and without co-evolution information. Prof. Jinbo Xu is an invited speaker at our annual conference on Oct. 15th and 16th. nature.com/articles/s4225…

Prof. Frederick W. Alt led his team from Harvard Medical School to present a humanized mouse model approach to diversify therapeutic antibodies. Prof. Frederick W. Alt is an invited speaker at our annual conference starting tomorrow!pnas.org/content/118/10…

BioNova Pharmaceuticals will develop and commercialize Sutro Biopharma’s STRO-001, a CD74-targeting site-specific #ADC for patients with hematologic cancers, in Greater China. ir.sutrobio.com/news-events/ne…

Merck’s Keytruda + chemo combo therapy wins FDA approval for first-line treatment of recurrent or metastatic cervical cancer. fda.gov/drugs/resource…

Dr. Thomas Pillow led a team from Genetech to improve the quality of calicheamicin ADCs by novel linker chemistry. mct.aacrjournals.org/content/20/6/1…(ADCs,CD22%20for%20acute%20lymphocytic%20leukemia

Welcome to join us at the 2021 Annual Conference of Chinese Antibody Society #TONIGHT. Live on Zoom, Free for All. chineseantibody.org/meetings/4th-C…

Virus-specific nanobody (VUN100bv) able to promote T-cell-mediated killing of latently infected monocytes in HCMV-seropositive individuals. nature.com/articles/s4146…

US FDA awarded Boehringer Ingelheim the first interchangeability designation for Cyltezo, a Humira biosimilar. endpts.com/boehringer-nab…

F-star Therapeutics, Inc. announces licensing agreement with The Janssen Pharmaceutical Companies of Johnson & Johnson to develop and commercialize up to five #bispecific antibodies using F-star’s proprietary Fcab™ and mAb2™ platforms. fiercebiotech.com/biotech/again-…

Development of monkey-human chimeric mAbs exhibiting efficient HBsAg-suppressing effects using a protein vaccine CR-T3-SEQ13 carrying validated hepatitis B surface antigen (HBsAg) epitope. academic.oup.com/abt/article/4/…

Antengene has entered into a Research Collaboration and License Option Agreement with LegoChem Biosciences for new #ADCs. en.prnasia.com/releases/apac/…

The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation.science.org/doi/10.1126/sc…

A new administration route for Genentech’s ranibizumab (anti-VEGF antibody fragment, marketed as Susvimo) for wet AMD is approved by the US FDA. endpts.com/just-as-first-…

Palleon Pharmaceuticals, a pioneer in glyco-immunology, will present preclinical updates on its I/O asset E-602 at #SITC2021. E-602 is a FIC Enzyme-Antibody fusion that utilizes engineered human sialidase to degrade immunosuppressive sialoglycans in the tumor microenvironment.

A combination of standard regulatory pathways, the flow of capital, supply of talents, business opportunities, and speed of execution makes China’s rise in biopharma in the past 20 years. Looking forward to more exciting achievements down the road. endpts.com/how-china-turn…

Perceptive Advisors-steered LianBio raised $325 million in a US IPO. Specialized in license-in strategies, LianBio has already curated nine programs across five therapeutic areas, including oncology, cardiovascular and inflammatory diseases. endpts.com/perceptive-ste…

HiFiBiO Therapeutics receives FDA clearance of IND application for HFB200301, a first-in-class anti-TNFR2 agonist mAb designed to promote antitumor responses by stimulating both innate and adaptive immune systems in solid tumors. hifibio.com/hifibio-therap…

Kintor Pharma (HKEX 9939) has dosed its first patient with advanced or refractory solid tumors in a phase Ib/II clinical trial of ALK-1 antibody (licensed from Pfizer) in combination with KN046 (a PD-L1/CTLA-4 bispecific antibody developed by Jiangsu Alphamab) in Taiwan, China.

Innovent Biologics (HKEX: 01801), a corporate member of CAS, published its preclinical results of IBI319 in Nature Communications today. IBI319 is a PD-1 x CD137 bispecific antibody. The IND for IBI319 has been cleared by China NMPA.